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Abstract
Background: Between 2% and 5% of malignant germ-cell tumors in men arise at extragonadal
sites. Of extragonadal germ cell tumors, testicular carcinoma in situ (CIS) are present in 31–42%
of cases, and CIS are reported to have low sensitivity to chemotherapy in spite of the various
morphology and to have a high likelihood of developing into testicular tumors. A testicular biopsy
may thus be highly advisable when evaluating an extragonadal germ cell tumor.
Case presentation: A 36-year-old man was diagnosed as having an extragonadal non-
seminomatous germ cell tumor, that was treated by cisplatin-based chemotherapy, leading to a
complete remission. In the meantime, testicular tumors were not detected by means of
ultrasonography. About 4 years later, a right testicular tumor was found, and orchiectomy was
carried out. Microscopically, the tumor was composed of seminoma.
Conclusions: We herein report a case of metachronous occurrence of an extragonadal and
gonadal germ cell tumor. In the evaluation of an extragonadal germ cell tumor, a histological
examination should be included since ultrasonography is not sufficient to detect CIS or minute
lesions of the testis.
Background
Between 2% and 5% of malignant germ-cell tumors in
men arise at extragonadal sites [1]. Cytogenetically most
extragonadal germ-cell tumors (EGGCTs) i.e., the semino-
mas and non-seminomas, are similar to their testicular
counterparts [2,3]. But there are CIS in 31–42% of EGGCT
patients' testes [4]. Ultrastructural studies indicate that
CIS originate from rather primitive cells and can develop
into different categories of germ cell carcinomas. Further-
more, since CIS are reported to respond poorly to chemo-
therapies, a metachronous development of testicular
cancer will possibly occur, in spite of the various mor-
phologies of testicular cancer [5,6]. In the present case, the
etiology of a metachronous appearance of EGGCT and
testicular cancer is discussed.
Case presentation
A 36-year-old man was admitted to our hospital with the
chief complaint of right-sided scrotal enlargement. He
had previously received treatment for an extragonadal
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bago. CT showed a retroperitoneal tumor (Figure 1), and
a transabdominal needle biopsy was carried out. Micro-
scopically, the tumor was composed of a yolk sac tumor
(Figure 2A,2B). We performed two courses of systemic
chemotherapy using bleomycin, etoposide, and cisplatin,
leading to a partial response. As the tumor size was not
seemed to decrease after the two courses of the chemo-
therapy, retroperitoneal lymph node dissection was per-
formed, but failed to show any residual viable cells. An
ultrasonic study did not reveal any testicular tumors.
About 4 years after the previous treatment, he presented
with scrotal enlargement and tumor markers such as AFP
and HCG β were within normal limit. A right orchiectomy
was performed on 23rd July. Pathology showed the
resected tumor was a seminoma with CIS (Figure 3A,3B).
No recurrence has been seen since the surgery (Figure 1B).
Conclusions
There are reports that approximately 4% of patients with
EGGCT develop a metachronous testicular cancer despite
the use of cisplatin-based chemotherapy [7], and the
cumulative risk of developing a metachronous testicular
cancer 10 years after a diagnosis of EGGCT is 10.3% [8].
However, there is disagreement over whether EGGCT is a
primary disease or metastatic from the burned-out pri-
mary testicular lesion. Actually, burned-out tumors have
been detected in 76% of cases of EGGCT [9]. CIS is also
found via biopsy in 31–42% cases [4,10]. Testicular CIS is
thought to have resistance to systemic chemotherapies
and to develop later to metachronous testicular cancer. In
the present case, the EGGCT was a non-seminomatous
germ cell tumor including a yolk sac component, whereas
the testicular cancer was a seminoma. We believe CIS was
present at the time of the treatment of EGGCT and
CT shows a retroperitoneal bulky massFigure 1
CT shows a retroperitoneal bulky mass. (B) The clinical 
course from the treatment of EGGCT to that of seminoma.
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Photomicrograph of extragonadal non-seminomatous germ cell u o  with a f cus of y lk s c tumorFigure 2
Photomicrograph of extragonadal non-seminomatous germ 
cell tumor with a focus of yolk sac tumor. A: H&E section 
shows characteristic structures suggestive of Schiller-Duval 
bodies (×200). B: Alpha-fetoprotein immunohistochemical 
stain is focally positive at the above area (×400).
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any type of germ cells. It is also possible that these meta-
chronously developing germ cell tumors developed inde-
pendently. A testicular biopsy could clarify the
relationship between these tumor cells and the expansion
of the disease. In the present case no biopsy was done, but
an ultrasonic examination ruled out the possibility of tes-
ticular CIS. Giwercman et al. [11] emphasized the neces-
sity of histological examinations of the testis upon an
evaluation of EGGCT [12-14] and also urged a careful fol-
low-up for patients with EGGCT who do not have simul-
taneous testicular cancer.
On the other hand, there is an opinion that any patients
with retroperitoneal masses should undergo scrotal
ultrasound. Comiter et al. [15] showed definite pathologi-
cal evidence of a burned-out testicular carcinoma in 5 of 6
patients (83%) with presumed extragonadal germ cell
tumors and concluded that scrotal ultrasound studies are
useful for the evaluation of the palpably normal testes [15].
Kitahara et al. reviewed the incidence of scrotal echogenic
leisions with testicular cancers or burned-out tumors of 22
EGGCT patients and found echogenic changes in 17
patients (77.3%) [16]. This means that disease was over-
looked by ultrasonic examinations in 22.7% of cases.
In our case, it is possibile that metachronous testicular
cancer oriented in testicular CIS, grew from a burned-out
tumor, or was independent of the EGGCT. We should
have performed testicular biopsies at the time of the diag-
nosis of EGGCT and reflect the strategies of treatments of
EGGCT.
Now we propose a surveillance protocol of EGGCT as
Table 1, concerning with following four points.
1. As we mentioned, the overall risk of development a tes-
ticular tumor is not so high(4–10.3%).
2. The side effect of CIS therapy (whether irradaition,
orchiectomy or chemotherapy) are significant, especially
concerning fertility and androgen production.
Photomicrograph of classic seminoma of the testisFigure 3
Photomicrograph of classic seminoma of the testis. A: H&E 
section shows compact nests of large tumor cells are sepa-
rated by thin fibrous septa infiltrated by lymphocytes. B: 
Intratubular germ cell neoplasia in H&E section (×100). A 
row of atypical germ cells with clear cytoplasm is seen against 
a thickened basement membrane. No spermatogenesis is 
occurring in this tubule (×200).
A
B
Table 1: Our proposed surveillance protocol of EGGCT is as below.
Testicular Biopsy At the time of the diagnosis
Self-check of the testis Every months
Scrotal ultrasound study -3 years -5 years -10 years
every 3 months every 6 months every year
Tumor markers -3 years -5 years -10 years
every 3 months every 6 months every year
CT(chest-pelvic) -3 years -5 years -10 years
every 3 months every 6 months every yearPage 3 of 4
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3. Testicular tumors early detected by adequate surveil-
lance respond well to treatments.
4. Testicular biopsy is not entitled to detect all the CIS.
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